Navigation Links
Swift Transportation donates more than $15,000 to the Waylon Fund
Date:12/13/2012

PHOENIX, Ariz. Dec. 13, 2012 Swift Charities, the charitable arm of Swift Transportation, today donated $15,262 to The Waylon Jennings Fund for Diabetes Research at the Translational Genomics Research Institute (TGen).

Throughout November Diabetes Awareness Month The Waylon Fund was Swift's "charity of choice." Half of November's proceeds from thousands of driver donations, as well as matching contributions from Phoenix-based Swift, were collected to benefit TGen's diabetes research in the name of country music legend Waylon Jennings.

In a letter to Swift drivers, Jennings' widow, Jessi Colter, urged them to remember her late husband, who died in 2002 of complications from diabetes, a disease that affects nearly 26 million Americans.

"Waylon Jennings was truly one-of-a-kind. Often thought of as an 'outlaw' and a mentor to a new generation of country and rock acts inspired by his spirit and individualism, he was above all someone who stood strong in the face of adversity," Colter said in her letter. "I am so pleased to announce TGen's new partnership with Jerry Moyes, the founder, chairman and CEO of Phoenix-based Swift Transportation. With the help of Swift Charities and Swift drivers from across the country, The Waylon Fund will spur innovative research at TGen to find better treatments for diabetes."

Jim Stone, Executive Director of Swift Charities, said his company's drivers were eager to answer Colter's call to action.

"Diabetes is one of many health issues that needs greater attention, and we at Swift are proud to partner with another Phoenix-based institution, TGen, to advance biomedical research in this critical area," Stone said. "To be able to do that in conjunction with Jessi Colter, and do it in the memory of Waylon Jennings, that is a real honor."

"TGen's research into diabetes will allow physicians to more accurately predict who has the greatest risk of developing Type 2 diabetes and related complications, while also identifying targets for treatment of the disease," said Dr. Johanna DiStefano, Director of TGen's Diabetes, Cardiovascular & Metabolic Diseases Division.

Dr. DiStefano leads a team of scientists working in five areas of research: diabetes and heart disease, diabetic nephropathy, diabetes and obesity, diabetes and liver disease, and diabetes and individualized treatment strategies.

"TGen is extremely grateful to the Swift Transportation family for supporting The Waylon Fund for Diabetes Research," said Michael Bassoff, President of the TGen Foundation. "This gift from Swift Charities is reflective of the dedication and generosity of Swift employees nationwide who individually contributed to help accelerate TGen's diabetes research."


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Jeff Crandall Honored With SAE International Arnold W. Siegel International Transportation Safety Award
2. To spread, nervous system viruses sabotage cell, hijack transportation
3. Plan to turn farm waste into paper earns students $15,000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
(Date:1/24/2017)... 24, 2017  It sounds simple and harmless—an ... monitors vital signs and alerts parents on their ... saturation level drops. But pediatric experts argue that ... with no evidence of medical benefits, especially to ... aggressively to parents of healthy babies, promising peace ...
(Date:1/19/2017)... , January 19, 2017 According to a new ... and Forecast, 2014 - 2022," the global biometric sensor market is expected to ... to 2022. In 2015, Asia-Pacific dominated the global market ... private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:2/25/2017)... ... February 25, 2017 , ... ... Clinical Trials in an ongoing effort to create meaningful change by increasing ... pharmaceutical research with emphasis on consumers and patients’ mental health well-being. , Both ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
Breaking Biology Technology: